Science of DME Newsfeed
- FDA approves faricimab for treatment of wet AMD and DME
- DRCR Network releases new data on Anti-VEGF response for diabetic macular edema
- Egypt has become the 31st country to approve aflibercept to treat diabetic retinopathy in patients with DME.
- The Angiogenesis Foundation Launches Nationwide Campaign for Saving Vision on World Sight Day
- People with Diabetes Have More Options: FDA Approves Anti-VEGF Agent Aflibercept for Diabetic Retinopathy
- Ranibizumab Vision Improvement Predicted by Retinal Venular Calibre
- Big news for people with diabetes: Anti-VEGF agent ranibizumab approved to treat diabetic retinopathy to prevent vision loss
- RIDE/RISE Extension Studies Demonstrate Sustained Visual Gains in DME Patients
- Novel Treatment Pathways for DME
- Ranibizumab Treatment 3-Year Outcomes Similar in DME Patients With and Without Vitrectomy
- Small Change, Big Rewards in A1c and Blood Pressure Control for Diabetes Patients
- The Angiogenesis Foundation Convenes the Canadian National Multistakeholder Expert Summit for Diabetic Macular Edema
- Anti-VEGF Agent Ranibizumab Gets FDA Breakthrough Therapy Designation for Diabetic Retinopathy
- Anti-VEGF Agent Aflibercept Approved in Canada for Treating Diabetic Macular Edema (DME)
- FDA Grants Priority Review of Antiangiogenic Agent Aflibercept for Treatment of Diabetic Retinopathy in DME Patients
- Antiangiogenic Agent Aflibercept Approved in Japan for Treatment of Diabetic Macular Edema
- Aflibercept injection shown to be superior to bevacizumab and ranibizumab in visual gains for DME patients
- Fluocinolone acetonide intravitreal implant (Iluvien) Gets FDA Approval for Treating Diabetic Macular Edema (DME)
- Dexamethasone Intravitreal Implant Gets EU Approval for Treatment of Diabetic Macular Edema
- Intravitreal aflibercept for DME improves vision better than laser
- FDA approves biodegradable dexamethasone intravitreal implant for the treatment of diabetic macular edema
- Anti-VEGF agent aflibercept gets EU Approval for Treatment of Diabetic Macular Edema (DME)
- FDA approves anti-VEGF agent aflibercept for treating Diabetic Macular Edema (DME)
- European commission recommends approval of anti-VEGF agent aflibercept for treatment of diabetic macular edema
- Antiangiogenic Agent Ranibizumab Approved in Japan for Treatment of Diabetic Macular Edema
- Diabetes ‘no longer leading cause of blindness’ in the UK